Holen Sie sich die Stockscreener-App
8.33
3.03%
-0.26
Handel nachbörslich:
8.27
-0.06
-0.72%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt NVAX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$8.59
Offen:
$8.61
24-Stunden-Volumen:
4.47M
Relative Volume:
0.74
Marktkapitalisierung:
$1.35B
Einnahmen:
$1.08B
Nettoeinkommen (Verlust:
$422.82M
KGV:
3.6535
EPS:
2.28
Netto-Cashflow:
$-637.33M
1W Leistung:
-11.95%
1M Leistung:
+4.65%
6M Leistung:
+53.41%
1J Leistung:
-35.45%
1-Tages-Spanne:
$8.24
$8.6869
1-Wochen-Bereich:
$8.24
$9.60
52-Wochen-Spanne:
$5.01
$13.34
Novavax Inc Stock (NVAX) Company Profile
Firmenname
Novavax Inc
Sektor
Branche
Telefon
240-268-2000
Adresse
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Vergleichen Sie NVAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
8.33 | 1.40B | 1.08B | 422.82M | -637.33M | 2.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-08-20 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2025-06-17 | Eingeleitet | Citigroup | Sell |
| 2025-02-28 | Eingeleitet | BTIG Research | Buy |
| 2024-07-30 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-05-10 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-05-10 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-08-09 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2023-04-20 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-03-01 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2023-01-09 | Bestätigt | B. Riley Securities | Buy |
| 2022-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2022-12-02 | Eingeleitet | Jefferies | Hold |
| 2022-09-22 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-05-20 | Eingeleitet | BofA Securities | Underperform |
| 2022-02-23 | Bestätigt | B. Riley Securities | Buy |
| 2022-02-22 | Fortgesetzt | Jefferies | Buy |
| 2022-01-21 | Eingeleitet | Cowen | Outperform |
| 2021-05-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
| 2020-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-05 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-08-05 | Herabstufung | Ladenburg Thalmann | Neutral → Sell |
| 2020-07-16 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-06-29 | Bestätigt | B. Riley FBR | Buy |
| 2020-06-29 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-05-28 | Bestätigt | B. Riley FBR | Buy |
| 2020-05-12 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-30 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-27 | Fortgesetzt | B. Riley FBR | Buy |
| 2019-08-14 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-28 | Herabstufung | Piper Jaffray | Overweight → Underweight |
| 2018-12-18 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-12-11 | Eingeleitet | Oppenheimer | Outperform |
| 2018-11-26 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-09-21 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2018-03-29 | Hochstufung | Seaport Global Securities | Neutral → Buy |
Alle ansehen
Novavax Inc Aktie (NVAX) Neueste Nachrichten
Will Novavax Inc. continue its uptrendPortfolio Return Summary & Expert Approved Momentum Trade Ideas - newser.com
Statistical indicators supporting Novavax Inc.’s strengthJuly 2025 Analyst Calls & Real-Time Volume Spike Alerts - newser.com
Analyzing Novavax Inc. with risk reward ratio chartsTrade Ideas & Long-Term Investment Growth Plans - newser.com
Is Novavax Inc. stock attractive after correctionWeekly Volume Report & Weekly High Conviction Ideas - newser.com
What analysts say about Novavax Inc NVV1 stockDividend Cut Warnings & Grow Steadily With Our Wealth Roadmap - earlytimes.in
Automated trading signals detected on Novavax Inc.2025 Volatility Report & Fast Entry High Yield Tips - newser.com
Is Novavax Inc. (NVV1) stock a buy on weakness2025 Pullback Review & Scalable Portfolio Growth Methods - newser.com
Is Novavax Inc. showing signs of accumulationMarket Performance Summary & Reliable Volume Spike Trade Alerts - newser.com
What institutional flow reveals about Novavax Inc.July 2025 Final Week & Fast Gain Stock Tips - newser.com
Novavax Inc Completes EU Marketing Authorization Transfer for Nuvaxovid - TradingView
Novavax Inc. Stock Slides 3.5%, Underperforms Peers - 富途牛牛
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know - Yahoo Finance
Novavax, Inc. Experiences Evaluation Revision Amid Mixed Market Performance Indicators - Markets Mojo
Novavax (NVAX) Transfers EU Vaccine Rights to Sanofi for $25M - GuruFocus
Novavax hands over Nuvaxovid marketing rights to Sanofi in the EU - Seeking Alpha
Novavax Continues to Deliver on Sanofi Partnership, Completion Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment - MarketScreener
Novavax Completes Transfer of Marketing Authorization for COVID-19 Vaccine in EU to Sanofi - MarketScreener
Sanofi (SNY) Gains Full EU Control of Nuvaxovid from Novavax - GuruFocus
Novavax receives $25 million milestone payment from Sanofi partnership - Investing.com
Novavax Transfers EU Vaccine Rights to Sanofi - TipRanks
Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment - Stock Titan
Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
Novavax Inc Stock Analysis and ForecastMerger & Acquisition Updates & Free Fastest Return On Investment - earlytimes.in
Is Novavax Inc. stock attractive for retirement portfoliosQuarterly Profit Review & Short-Term High Return Strategies - newser.com
Will Novavax Inc. (NVV1) stock benefit from sector leadershipJuly 2025 Short Interest & Weekly Top Performers Watchlists - newser.com
Smart tools for monitoring Novavax Inc.’s price actionMarket Growth Summary & Breakout Confirmation Alerts - newser.com
Will Novavax Inc. outperform the marketStop Loss & Verified Momentum Stock Watchlist - newser.com
Can Novavax Inc. rally from current levelsTrade Volume Report & AI Powered Buy/Sell Recommendations - newser.com
Using Bollinger Bands to evaluate Novavax Inc.Analyst Downgrade & High Yield Stock Recommendations - newser.com
Will Novavax Inc. stock benefit from AI adoptionQuarterly Growth Report & High Accuracy Investment Entry Signals - newser.com
Analyzing recovery setups for Novavax Inc. investorsWeekly Trade Summary & Weekly High Return Forecasts - newser.com
Novavax (NVAX) Is Up 10.6% After Sanofi Expands Matrix-M Licensing AgreementHas the Bull Case Changed? - Yahoo Finance
Novavax Inc. (NVAX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
A Fresh Look at Novavax (NVAX) Valuation After Recent Share Price Rebound - Yahoo Finance
Novavax allows Sanofi to use Matrix-M adjuvant for pandemic flu candidate - MSN
Novavax, Inc. (NASDAQ:NVAX) Held Back By Insufficient Growth Even After Shares Climb 27% - 富途牛牛
Noteworthy Wednesday Option Activity: ONON, NVAX, COMM - Nasdaq
Novavax’s Vaccine Milestone and Market Movement - StocksToTrade
Novavax expands Sanofi partnership for pandemic flu vaccine development By Investing.com - Investing.com Nigeria
Novavax (NVAX) Expands License for Matrix-M with Sanofi - GuruFocus
Novavax (NVAX) Exceeds Market Returns: Some Facts to Consider - sharewise.com
Novavax Deepens Partnership with Sanofi: Matrix-M Adjuvant Set to Bolster Pandemic Influenza Vaccine Development - BBN Times
Finanzdaten der Novavax Inc-Aktie (NVAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Novavax Inc-Aktie (NVAX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Alton Gregg H | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
28,805 |
| King Rachel K. | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
25,190 |
| Rodgers Richard J | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
24,690 |
| MOTT DAVID M | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
60,890 |
| DOUGLAS RICHARD | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
54,340 |
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):